Tipifarnib Gets Breakthrough Therapy Designation for HRAS-Mutated HNSCC
February 25, 2021
The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.